reason report
recap could l-mind approv europ els
bottom line yesterday even morphosi report
fy financi result provid financi guidanc
updat clinic regulatori progress key
program compani remain track submit regulatori
applic us year-end appear
receiv posit indic regul europ
potenti file base l-mind well file
proce could becom signific catalyst investor later
mor continu indic potenti partnership
ex us right announc
partnership provid signific cash perform
oblig partner could also prove import
catalyst stock
major regulatori commerci activ plan
expect investor alreadi anticip accept us bla
accept l-mind europ could major catalyst
pull forward eu sale expect year also expect
morphosi stock benefit clarif plan
addit indic outsid diffus larg b-cell lymphoma cell
compani confirm disclosur like occur mid-year
like updat data l-mind june offset
opportun manag guidanc suggest pre-launch
expens higher previous model
updat expens forecast lower price target
adr despit chang continu view stock
posit provid rel straightforward path
signific valu creation come month
dcf analysi discount rate
year price history/av daili volume mil mor gy
compani inform svb leerink llc research
revenu mm
pleas refer page import disclosur price chart analyst certif
price target morphosi mor us adr rate stock
outperform morphosi german biopharmaceut compani long legaci innov
therapeut monoclon antibodi discoveri develop histor morphosi taken
care path build broad portfolio skinni collabor bigger biopharma
compani result potenti low-to-mid singl digit royalti product
collabor final come fruition first reach market
tremfya begin gener royalti morphosi larger basi
compani valu howev morphosi wholly-own
hematolog malign shown impress data single-arm phase ii trial
patient transplant-inelig relaps refractori dlbcl endors
us fda data appear suffici acceler approv
abl gener revenu rang mid still potenti
develop larger popul sever differ form nhl import
asset mor stock royalti jnj antibodi psoriasi estim
worth today could increas substanti revenu exce perform
product indic royalty-bear product agreement contribut anoth
compani outstand cash reserv add anoth give total
result show grow tremfya royalti increas spend morphosi
report revenu tremfya royalti licens payment total expens
doubl sequenti due time certain payment
earli invest sale expens morphosi report net loss
per share basi
guidanc suggest increment spent commerci
activ morphosi guid revenu tremfya
royalti payment compani expect spend proprietari combin
grow sell expens budget build-up commerci suppli expect
ebit squar ebit loss revenu expect
appear morphosi implicitli guid sg expens around doubl
expens report morphosi state guidanc includ potenti
larger mileston initi phase trial gm-csf
potenti futur partnership licens agreement occur morphosi
expect gsk initi phase trial associ mileston payment could
substanti off-set step commerci expens
l-mind track year-end bla morphosi first independ product applic
later year file base l-mind single-arm trial
transplant-inelig relapsed/refractori diffus larg b-cell lymphoma
dlbcl l-mind alreadi reach primari complet patient enrol
compani clean data morphosi present final result upcom medic
confer potenti intern confer malign lymphoma icml late june
updat result includ bla morphosi expect submit
year-end potenti launch
b-mind trial biomark chang ad co-primari endpoint analysi
morphosi recent announc amend b-mind trial discuss
fda see note being-mind regulatori hurdl trial amend lower
approv risk compani ad co-primari endpoint test progress free
surviv benefit versu rituximab bendamustin
subpopul enrich presenc certain undisclos biomark test
alongsid intent treat popul morphosi expect report interim data b-mind
depend outcom may increas trial size patient
recruit patient biomark expans occur would delay full primari
analysi
expedit european approv still possibl morphosi state call
two discuss european regul possibl use l-mind
basi approv compani origin thought european regul would requir
random trial b-mind approv believ europ recept
single-arm l-mind trial given strong benefit shown data chang stanc
ema toward singl arm trial compani describ progress europ earli
encourag compani meet european regul summer
could receiv statement recommend agenc suitabl l-mind
basi approv
morphosi reiter plan start first frontlin studi dlbcl year
phase ib studi full l-mind result present mid-year compani
like outlin develop plan drug includ investig initi trial
iit compani sponsor studi disclosur could includ novel combin
dlbcl plan follicular lymphoma possibl exploratori studi set
indic morphosi also plan start exploratori clinic trial
antibodi undisclos autoimmun indic compani specif interest
diseas presenc pathogen autoantibodi correl diseas activ
pemphigu exploratori trial test abil reduc
autoantibodi thu modifi diseas
enter solid cash posit estim morphosi
finish year cash three year runway current level
spend grow tremfya royalti potenti mileston payment exist futur
partnership could extend runway even investor expect significantli higher
expens next year
model updat pt adr updat morphosi model trend
quarter guidanc provid manag increas forecast
licens revenu lower later year captur
slightli lower tremfya royalti rate expens increas estim
increas sg forecast captur pre-
launch cost previous model ep forecast lower
year heavili impact decreas continu
forecast break-even morphosi base chang new price target
dcf adr
price target mor base dcf methodolog cash flow
termin growth driver forecast royalti tremfya risk-adjust
sale risk-adjust royalti assum discount rate
base compani wacc also includ valuat gantenerumab
royalti stake base compar anti-amyloid transact addit factor mor
cash balanc valuat
risk view outlook valuat morphosi includ failur obtain approv
either us ex-u jurisdict base l-mind forecast
product also subject risk better-than-expect market share gain competit
brand product roch polatuzumab lack willing physician
patient chang new treatment long-stand treatment option
payer us europ could also refus reimburs expens combin
plu revlimid could potenti cost year treatment
addit morphosi current sole sourc incom royalti tremfya could lower
expect due chang highli competit immunolog treatment market risk
morphosi includ develop regulatori disappoint partner out-
licens antibodi two product fail compani valuat would reduc
approxim
pipelin program includ current model
pipelin program exclud current
brand chemic name
type event
event trial detail
date known
specifi
up/down
svb leerink view event
possibl intern confer
collabor annouc
partnership ex us right
svb leerink llc research compani file
million
royalti mileston po adjust
svb leerink llc research compani file
million
sale
 total revenu
sg total revenu
svb leerink llc research compani file
mm
pv flow
equiti
debt
